Aclarion, Inc. (NASDAQ:ACON) Stock Short Interest Falls 35.6%

Posted by Brian Himes on Oct 16th, 2026

Aclarion, Inc. (NASDAQ:ACON – Get Free Report) was the target of a large decrease in short interest in September. As of September 30th, there was short interest totaling 48,934 shares, a decrease of 35.6% from the September 15th total of 76,007 shares. Currently, 1.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 62,470 shares, the short-interest ratio is currently 0.8 days.

Aclarion Stock Performance

NASDAQ ACON opened at $1.95 on Friday. The stock has a fifty day moving average of $2.44 and a 200-day moving average of $2.84. The stock has a market capitalization of $5.63 million, a P/E ratio of -0.26 and a beta of 1.20. Aclarion has a 52 week low of $1.89 and a 52 week high of $9.36.

Aclarion (NASDAQ:ACON – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). Aclarion had a negative return on equity of 59.34% and a negative net margin of 10,948.81%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Equities research analysts forecast that Aclarion will post -4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ACON shares. Wall Street Zen upgraded shares of Aclarion from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings raised shares of Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.50.

View Our Latest Research Report on ACON

Insider Transactions at Aclarion

In related news, Director Ryan Bond acquired 21,122 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were purchased at an average price of $2.37 per share, with a total value of $50,059.14. Following the acquisition, the director directly owned 76,122 shares in the company, valued at $180,409.14. The trade was a 38.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders have bought 51,863 shares of company stock worth $125,670. 0.01% of the stock is owned by corporate insiders.

About Aclarion

(Get Free Report)

Aclarion, Inc (NASDAQ: ACON) is a healthcare technology company focused on improving the diagnosis and treatment planning of chronic low back pain. The company develops software designed to help physicians identify the spinal discs that may be contributing to a patient’s pain.

Its primary product, Nociscan, is a cloud-based platform that analyzes magnetic resonance spectroscopy data along with other imaging information. The system generates quantitative assessments, including Nociscores, intended to provide additional insight into disc health and support physicians in evaluating potential treatment options.

Aclarion’s technology is designed for use by spine specialists, radiologists, imaging centers and other healthcare providers.